|
21 Dec 2019 |
Johnson & Johnson Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder Cancer
|
|
21 Dec 2019 |
Bristol-Myers Squibb Receives European Commission Approval for Revlimid® (lenalidomide) in Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma
|
|
21 Dec 2019 |
Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
|
|
21 Dec 2019 |
ENHERTU® Approved in the U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2-Based Regimens
|
|
21 Dec 2019 |
ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV
|
|
20 Dec 2019 |
Vaccitech Oncology Limited Enters Collaboration with Cancer Research UK to Fund a Phase I/IIa Clinical Trial as First-Line NSCLC Therapy
|
|
20 Dec 2019 |
MC2 Therapeutics Announces Positive Top-line Results from EU Phase 3 Head-to-Head Trial Comparing Wynzora™ Cream to Daivobet® Gel in Patients with Psoriasis
|
|
20 Dec 2019 |
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement
|
|
20 Dec 2019 |
Solid Biosciences Provides Data Update from SGT-001 Development Program
|
|
20 Dec 2019 |
Chondrial Therapeutics Announces Dosing of First Patients in Phase 1 Clinical Program of CTI-1601 for Treatment of Friedreich’s Ataxia
|
|
20 Dec 2019 |
GBT and Syros Partner to Discover, Develop and Commercialize Novel Therapies for Sickle Cell Disease and Beta Thalassemia
|
|
20 Dec 2019 |
ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa
|
|
20 Dec 2019 |
Ultragenyx Announces Sale of Future European Royalties on Crysvita® (burosumab) for $320 Million to Royalty Pharma
|
|
20 Dec 2019 |
Inventiva announces positive results from Phase IIa clinical study with odiparcil in mucopolysaccharidosis type VI
|
|
20 Dec 2019 |
Rezolute, Inc. Announces Top-line Results from Phase 1 Trial Evaluating AB101 in Patients with Diabetes
|
|
20 Dec 2019 |
Akcea Retains Rights to AKCEA-APOCIII-LRx
|
|
20 Dec 2019 |
European Commission approves Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
|
|
20 Dec 2019 |
NexImmune Receives IND Clearance for Phase 1/2 Trial in Relapsed / Refractory Multiple Myeloma
|
|
20 Dec 2019 |
Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration
|
|
20 Dec 2019 |
AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease
|
